|
BUY THIS REPORT NOW
Publication Date: October 2004
Pages: 232
Purchasing Info
Single User: $1500
Site/Department: $2999
Global/Enterprise: $4999
There are currently over twenty Phase III trials ongoing for various indications and new approvals may come as early as 2005. The value of the market for cancer vaccines has the potential to reach $6 billion by 2010.
This report is designed to provide the information, insight and analysis key to an understanding of how cancer vaccines will impact the biotech and pharmaceutical marketplace. Those in the field of cancer therapy and cancer vaccines will want to read this report in order to better understand where and how vaccines will make a difference in future cancer therapy.
This 232-page report:
- Gauges the potential of key vaccine products nearing commercialization.
- Analyzes the results of key clinical trials as a means of determining future success in the market.
- Forecasts financial growth of the cancer vaccine market through 2010.
- Assesses the competition from cytotoxics and other biologics in six key cancer markets.
- Provides valuable data concerning patient populations, survival rates, and global epidemiology
- Identifies and discusses trends and issues that will have a significant impact on the cancer vaccine market.
- Profiles the leading companies in the field and provides valuable information and analysis concerning their lead vaccine candidates.
Table of Contents
1 Methodology and Executive Summary
1.1 Report Objectives
1.2 Research Methodology
1.3 Executive Summary
Table 1.1 Value of the Cancer Vaccine Market, by Type, 2010
2 The Global Impact of Cancer
2.1 United States
Table 2.1 Estimated New Cancer Cases and Deaths, US 2004
Graph 2.1 Deadliest Cancers in the US 2004
Graph 2.2 Leading Sites of New Cancer Cases, Male 2004
Graph 2.3 Leading Sites of New Cancer Cases, Female 2004
2.2 The World
Table 2.2 Total Incidence of Cancer, by Region 2000
Graph 2.4 Regions Most-Effected by Cancer, 2000
Table 2.3 Rates of Incidence and Deaths for Select Cancers Worldwide, 2000
2.3 Survival Rates
Table 2.4 Five-Year Survival Rates for Select Cancers by Stage at Diagnosis, US 2000
2.4 Economic Impact
Table 2.5 The Economic Impact of Cancer in the US
2.5 Epidemiology of Select Cancers
2.5.1 Colorectal Cancer
2.5.2 Lung Cancer
Table 2.6 Global Lung Cancer Incidence in Select Regions, 2000
2.5.3 Prostate Cancer
Graph 2.5 Global Prostate Cancer Incidence, Select Regions, 2000
2.5.4 Breast Cancer
Table 2.7 Breast Cancer Survival Rates, by Stage
Table 2.8 Breast Cancer Overall Survival Rate
2.5.5 Pancreatic Cancer
Graph 2.6 Pancreatic Cancer Incidence, Select Regions, 2000
2.5.6 Melanoma
Graph 2.7 Incidence of Melanoma, US vs. Rest of World, 2000
3 Introduction to Cancer Vaccines
3.1 The Immune System and Cancer
3.2 The Basics
3.3 Unmet Need in Cancer Therapy
3.4 Why Vaccines?
3.5 Early Efforts at Cancer Vaccines
3.6 Types of Vaccines
3.6.1 Viral Vectors and DNA Vaccines
3.6.2 Antigen/adjuvant Vaccines
3.6.3 Whole-cell Tumor Vaccines
3.6.4 Anti-Idiotype Vaccines
3.6.5 Dendritic Cell Vaccines
Table 3.1 Key Vaccines Nearing FDA Approval
4 Vaccines and the Future of the Colorectal Cancer Therapy Market
4.1 Current Treatment of Colorectal Cancer
Table 4.1 The Stages of Colorectal Cancer
4.1.1 Surgery
4.1.2 Radiation Therapy
4.1.3 Cytotoxics
4.1.4 Biologics
4.2 An Overview of the Market for Colorectal Cancer Therapies
Table 4.2 Leading Drugs for Treatment of Colorectal Cancer
Table 4.3 Sales of New Biologic Therapies for Colorectal Cancer 2004
Graph 4.1 Growth of the Colorectal Cancer Therapy Market, 2000-2004
Graph 4.2 The Colorectal Cancer Therapy Market, Cytotoxics vs. Biologics 2004
4.2.1 Cytotoxics
4.2.1.1 Eloxatin
4.2.1.1.1 Market Impact
4.2.1.2 Camptosar
4.2.1.2.1 Market Impact
4.2.2 Emerging Biologics with Strong Market Potential
4.2.2.1 Avastin
4.2.2.1.1 Market Impact
4.2.2.2 Erbitux
4.2.2.2.1 Market Impact
4.3 Unmet Need in Colorectal Cancer Therapy
4.4 The Promise of Vaccines for Colorectal Cancer
Table 4.4 Therapeutic Vaccine Pipeline for Colorectal Cancer
Graph 4.3 Therapeutic Vaccines for Colorectal Cancer, by Clinical Trial Phase
4.4.1 Clinical Trial Strategies
4.4.2 Oncovax
4.4.2.1 Clinical Trials
4.4.3 IGN101
4.4.3.1 Clinical Trials
4.4.4 Oncophage
4.4.4.1 Clinical Trials
4.4.5 Avicine
4.4.5.1 Clinical Trials
4.4.6 Theratope
4.4.6.1 Clinical Trials
4.5 Market Analysis: Colorectal Cancer Therapy Market and the Prospects for Vaccines
4.6 Financial Forecast for Colorectal Cancer Vaccines
Table 4.5 Oncovax Sales Forecast 2005-2010 ($ mn)
5 Vaccines and the Future of Prostate Cancer Therapy
5.1 Current Treatment of Prostate Cancer
Table 5.1 The Stages of Prostate Cancer
5.1.1 Surgery
5.1.2 Radiation Therapy
5.1.3 Hormone Therapy
5.1.4 Cytotoxics
Table 5.2 Best-Selling Hormone Therapies for Prostate Cancer
5.2 An Overview of the Market for Prostate Cancer Therapies
Table 5.3 Leading Drugs for Treatment of Prostate Cancer
Graph 5.1 Value of the Prostate Therapy Market 2000-2003
5.3 New Biologic Competitors in Prostate Cancer Therapy
5.4 Unmet Need in Prostate Cancer Therapy
5.5 The Promise of Vaccines for Prostate Cancer
Table 5.4 Therapeutic Vaccine Pipeline for Prostate Cancer
Graph 5.2 Therapeutic Vaccines for Prostate Cancer, by Clinical Trial Phase
5.5.1 Clinical Trial Strategies
5.5.2 Provenge
5.5.2.1 Clinical Trials
5.5.3 GVAX
5.5.3.1 Clinical Trials
5.5.4 MVA-Muc1- IL2
5.5.4.1 Clinical Trials
5.5.5 Prostvac-VF
5.5.5.1 Clinical Trials
5.6 Market Analysis: Prostate Cancer Therapy Market and the Prospects for Vaccines
5.7 Financial Forecast for Prostate Cancer Vaccines
Table 5.5 Prostate Cancer Vaccines Sales Forecast 2006-2010
Graph 5.3 Prostate Cancer Vaccine Market Share 2007
Graph 5.4 Prostate Cancer Vaccine Market Share 2010
6 Vaccines and the Future of the Lung Cancer Therapy Market
6.1 Current Treatment of Lung Cancer
Table 6.1 Stages of Lung Cancer
6.1.1 Surgery
6.1.2 Cytotoxics
6.1.3 Radiation Therapy
6.2 An Overview of the Market for Lung Cancer Therapies
Table 6.2 Leading Drugs for Treatment of Lung Cancer
Graph 6.1 Value of the Lung Cancer Therapy Market 2000-2003
Table 6.3 Major Uses for Popular Anti-Cancer Agents
Table 6.4 Sales of New Targeted Therapies for Lung Cancer 2004
Table 6.5 Therapeutic Vaccine Pipeline for Lung Cancer
Graph 6.2 Therapeutic Vaccines for Lung Cancer, by Clinical Trial Phase
6.2.1 Cytotoxics
6.2.2 New Targeted Therapies Increase Competition
6.2.2.1 Iressa
6.2.2.2 Tarceva
6.3 Unmet Need in Lung Cancer Therapy
6.4 Emerging Vaccines for Lung Cancer
6.4.1 Clinical Trial Strategies
6.4.2 IGN101
6.4.2.1 Clinical Trials
6.4.3 IMC-BEC2
6.4.3.1 Clinical Trials
6.4.4 BLP25
6.4.4.1 Clinical Trials
6.4.5 GVAX
6.4.5.1 Clinical Trials
6.5 Market Analysis: Lung Cancer Therapy Market and the Prospects for Vaccines
6.6 Financial Forecast for Lung Cancer Vaccines
Table 6.6 Lung Cancer Vaccines Sales Forecast 2006-2010
Graph 6.3 Lung Cancer Vaccine Market Share 2007
Graph 6.4 Lung Cancer Vaccine Market Share 2010
7 Vaccines and the Future of Breast Cancer Therapy
7.1 Current Treatment of Breast Cancer
Table 7.1 Stages of Breast Cancer
7.1.1 Surgery
7.1.2 Radiation Therapy
7.1.3 Hormone Therapy
7.1.4 Cytotoxics
7.1.5 Targeted Therapies
7.2 An Overview of the Market for Breast Cancer Therapies
Table 7.2 Leading Drugs for Treatment of Breast Cancer
Graph 7.1 Breast Cancer Therapies Market Share 2003
7.3 Unmet Need in Breast Cancer Therapy
7.4 Emerging Vaccines for Breast Cancer
Table 7.3 Therapeutic Vaccine Pipeline for Lung Cancer
Graph 7.2 Therapeutic Vaccines for Breast Cancer, by Clinical Trial Phase
7.4.1 Theratope
7.4.1.1 Clinical Trials
7.4.2 IGN101
7.4.2.1 Clinical Trials
7.5 Market Analysis: Breast Cancer Therapy Market and the Prospects for Breast Cancer Vaccines
Table 7.4 Breast Cancer Vaccines Sales Forecast 2007-2011
8 Vaccines and the Future of Pancreatic Cancer Therapy
8.1 Current Treatment of Pancreatic Cancer
Table 8.1 Stages of Pancreatic Cancer
8.1.1 Surgery
8.1.2 Radiation Therapy
8.1.3 Cytotoxics
8.2 Biologics in Development
Table 8.2 Biologics in Clinical Development for Pancreatic Cancer
8.3 An Overview of the Market for Pancreatic Cancer Therapy
Table 8.3 Leading Drugs for Treatment of Pancreatic Cancer
8.4 Unmet Need in Pancreatic Cancer Therapy
8.5 Emerging Vaccines for Pancreatic Cancer
Table 8.4 Therapeutic Vaccine Pipeline for Pancreatic Cancer
Graph 8.1 Therapeutic Vaccines for Pancreatic Cancer, by Clinical Trial Phase
8.5.1 Clinical Trial Strategies
8.5.2 INSEGIA (G17DT)
8.5.2.1 Clinical Trials
8.5.3 Virulizin
8.5.3.1 Clinical Trials
8.5.4 PANVAC-VF
8.5.4.1 Clinical Trials
8.5.5 Avicine
8.5.5.1 Clinical Trials
8.6 Market Analysis: Pancreatic Cancer Therapy Market and the Prospects for Vaccines
8.7 Financial Forecast for Pancreatic Cancer Vaccines
Table 8.5 Pancreatic Vaccine Approvals and Their Initial Indications
Table 8.6 Pancreatic Cancer Vaccines Sales Forecast 2006-2010
9 Vaccines and the Future of Melanoma Therapy
9.1 Current Treatment of Melanoma
Table 9.1 Stages of Melanoma
9.1.1 Surgery
9.1.2 Chemotherapy
9.1.3 Radiation Therapy
9.1.4 Biologics
Table 9.2 Currently Available Biological Therapies for Melanoma
9.2 An Overview of the Market for Melanoma Therapy
Table 9.3 Single-Agent Cytotoxics for Melanoma
Table 9.4 Leading Drugs for Treatment of Melanoma
9.3 Unmet Need
9.4 Emerging Vaccines for Melanoma
Table 9.5 Therapeutic Vaccine Pipeline for Melanoma
9.4.1 Canvaxin
9.4.1.1 Clinical Trials
9.4.2 Oncophage
9.4.2.1 Clinical Trials
9.4.3 Allovectin-7
9.4.3.1 Clinical Trials
9.5 Disappointments and Challenges in Melanoma Vaccine Development
9.5.1 GMK
9.5.2 Melacine
9.6 Market Analysis: Melanoma and the Prospects for Vaccines
Table 9.6 Competition in the Melanoma Therapy Market
9.7 Financial Forecast for Melanoma Vaccines
Table 9.7 Melanoma Vaccines Sales Forecast 2006-2010
10 Company Briefs
Aastrom Biosciences
Advaxis
Table 10.1 Advaxis' Cancer Vaccine Pipeline
AlphaVax
Antigenics
Table 10.2 Clinical Development Status of Oncophage
Aphton Corporation
Aventis Pasteur
AVI Biopharma
Biomira
Table 10.3 Biomira's Vaccine Pipeline
Biovex
CancerVax Corporation
Cell Genesys
Table 10.4 Clinical Development of GVAX
Corixa
Cytogen Corporation
Dendreon
Table 10.5 Dendreon's Vaccine Pipeline
Epimmune
Favrille Inc.
GeneMax
Genitope Corporation
Genzyme (Oncology)
Table 10.6 Genzyme's Vaccine Pipeline
Geron Corporation
GlaxoSmithKline Biologicals
IDM, Inc.
Table 10.7 IDM's Vaccine Pipeline
Igeneon
Table 10.8 Igeneon's Vaccine Pipeline
ImClone Systems Incorporated
Intracel Holdings Corporation
Large Scale Biology Corporation
Lorus Therapeutics
Maxygen
MedImmune
Merck & Co.
Northwest Biotherapeutics
Oxford BioMedica plc
Pharmexa A/S
Table 10.9 Pharmexa's Cancer Vaccine Pipeline
Progenics Pharmaceuticals
Table 10.10 Progenics' Cancer Vaccine Pipeline
Therion Biologics Corporation
Table 10.11 Therion's Cancer Vaccine Pipeline
Transgene S.A.
United Biomedical
Vical Incorporated
Xcyte Therapies Inc.
Table 10.12 Xcyte Therapies Vaccine Pipeline
YM Biosciences Inc.
Zycos
Appendix
Table I Cancer Vaccines in Clinical Development
Table II Anticipated Launches of Emerging Cancer Vaccines
Graph I Vaccines in Preclinical to Phase III Development Stages, by Indication
Graph II Leading Companies in Field of Cancer Vaccines
Graph III Number of Vaccine Indications in Clinical Trials, by Phase
Graph IV Leading Cancer Indications for Vaccines
Graph V Vaccines with Greatest Number of Potential Indications |
